Lenvatinib

Introduction Overview

Generic Name

lenvatinib

Brand Name

Lenvima, Lenvima 8 mg daily-dose, Lenvima 20 mg daily-dose, Lenvima 12 mg daily-dose

Dosage Form

oral capsule

Drug Class

Multikinase inhibitors, VEGF/VEGFR inhibitors

Pharmacokinetics

Absorption:
Lenvatinib is rapidly absorbed following oral administration, with peak plasma concentrations typically reached within 1 to 4 hours after dosing. The oral bioavailability is high, allowing effective systemic exposure through oral capsules. Food does not have a clinically significant effect on the absorption of lenvatinib; therefore, it can be taken with or without food, facilitating flexible dosing. The absorption kinetics are consistent, supporting once-daily dosing regimens. Clinical pharmacokinetic studies demonstrate that steady-state plasma concentrations are typically attained within 7 days of repeated daily dosing.

Distribution:
Lenvatinib exhibits extensive distribution throughout the body, with an apparent volume of distribution approximating 160 L, indicating distribution beyond the vascular compartment into tissues. It is moderately bound to plasma proteins, primarily albumin, with a protein binding rate of approximately 97%. Due to its high protein binding, displacement interactions may be a consideration when co-administered with other highly protein-bound drugs. The drug’s penetration into extravascular tissues, including tumor tissues, supports its efficacy in inhibiting tumor angiogenesis and growth. Tissue distribution studies emphasize its ability to reach target tissues relevant to its anticancer activity.

Metabolism:
Metabolism of lenvatinib occurs predominantly in the liver, primarily via oxidative pathways facilitated by cytochrome P450 (CYP) enzymes, including CYP3A4, as well as by non-CYP-mediated metabolic routes. The metabolic process results in multiple metabolites, none of which are known to be pharmacologically active. The metabolism is subject to interindividual variability based on hepatic enzyme activity but generally does not necessitate dose adjustment in mild to moderate hepatic impairment. In vitro studies and clinical data suggest limited inhibitory or inductive effects on major CYP enzymes, minimizing the potential for drug-drug interactions through metabolic pathways.

Elimination:
Lenvatinib is eliminated mainly through hepatic metabolism, with subsequent excretion of metabolites primarily via feces and to a lesser extent in urine. The terminal elimination half-life of lenvatinib ranges between approximately 28 to 35 hours, supporting once-daily dosing. In patients with impaired renal function, lenvatinib exposure may increase modestly, but dose adjustments are generally guided by clinical judgement. Similarly, in hepatic impairment, exposure changes may occur, therefore monitoring for toxicity is advised. The drug does not undergo significant renal clearance in unchanged form. Studies have demonstrated that elimination through enterohepatic circulation may contribute to prolonging systemic exposure. These pharmacokinetic parameters provide a foundation for dosing regimens used in clinical practice for advanced malignancies.

Dosage Forms

Available Dosage Forms:
Lenvatinib is formulated as oral capsules designed to provide flexible dosing options accommodating different cancer treatment requirements. The available capsule strengths include 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 18 mg, 20 mg, and 24 mg. These capsules can be used alone or in combination to achieve precise daily doses tailored to individual patient needs. The capsules should be swallowed whole; however, instructions are available for patients who have difficulty swallowing, allowing dissolution in water or apple juice followed by immediate ingestion.

Dosages for Adults and Adolescents:
- Thyroid Cancer: The recommended dose is 24 mg orally once daily. Treatment should continue until disease progression or unacceptable toxicity occurs. This dosage is for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
- Renal Cell Carcinoma (in combination with everolimus): 18 mg orally once daily, combined with 5 mg everolimus. Therapy is maintained until progression or toxicity precludes further use.
- Hepatocellular Carcinoma: Dosage is weight-based; for patients weighing less than 60 kg, 8 mg orally once daily; for patients 60 kg or greater, 12 mg orally once daily, until disease progression or unacceptable toxicity.
- Endometrial Carcinoma (in combination with pembrolizumab): 20 mg orally once daily, with pembrolizumab administered intravenously at 200 mg every 3 weeks. Treatment persists until progression or toxicity precludes continuation.

Specific Patient Populations:
Dose adjustments may be required based on tolerability, hepatic or renal impairment, and concomitant medications. For patients with renal or hepatic dysfunction, careful monitoring is required due to altered pharmacokinetics and potential accumulation. There is no established pediatric dosing; lenvatinib is primarily indicated for adult cancer populations. The presence of pre-existing cardiovascular conditions, bone disorders, or dental health issues warrants dose modification and close monitoring due to risks of adverse events. Dose titration and interruption strategies are employed to manage toxicity while maintaining therapeutic efficacy.

Mechanism Of Action

Lenvatinib is a highly potent, orally active multikinase inhibitor that targets multiple receptor tyrosine kinases implicated in tumor proliferation and angiogenesis. It selectively inhibits vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, FGFR4), platelet-derived growth factor receptor alpha (PDGFRα), as well as RET and KIT receptors. This broad spectrum of kinase inhibition allows lenvatinib to disrupt several critical signaling pathways that tumors use to promote angiogenesis, growth, and metastasis.

The primary molecular mechanism involves blockade of VEGFR-mediated signaling, which is essential for angiogenesis — the formation of new blood vessels that supply nutrients and oxygen to tumors. By inhibiting VEGFR phosphorylation and subsequent downstream signaling cascades like the PI3K/AKT and MAPK pathways, lenvatinib suppresses endothelial cell proliferation and migration, effectively starving tumor tissue of its blood supply.

In parallel, the inhibition of FGFRs disrupts alternative angiogenic and proliferative pathways that contribute to tumor growth and resistance mechanisms. FGFR signaling is critical in diverse cancers for maintaining tumor cell survival and vascular development, so its blockade enhances lenvatinib’s efficacy. The drug’s activity against PDGFRα additionally compromises the tumor microenvironment, further impairing vascular stabilization and supporting stromal interactions.

By targeting multiple kinase pathways concurrently, lenvatinib exerts a comprehensive anti-angiogenic and antitumor effect. This multi-targeted approach distinguishes lenvatinib from more selective anti-angiogenic agents and supports its clinical utility across a variety of solid tumors, including differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and endometrial carcinoma. Clinical studies confirm that this mechanism results in delayed tumor progression, reduced metastasis, and improved progression-free survival in treated patients. Comparatively, lenvatinib has demonstrated non-inferior overall survival relative to sorafenib in hepatocellular carcinoma but exhibits different side effect profiles and targeting breadth.

Pharmacological Actions

Inhibition of receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT.
Suppression of tumor angiogenesis via blockade of VEGFR-mediated endothelial cell signaling.
Interruption of fibroblast growth factor signaling pathways that promote tumor cell proliferation and angiogenesis.
Reduction of tumor vascularization and microenvironment support leading to inhibition of tumor growth.
Induction of tumor cell apoptosis through disruption of key survival signaling cascades (PI3K/AKT, MAPK).
Broad-spectrum multikinase inhibition overcoming resistance mechanisms seen with single-target agents.
Synergistic antitumor activity when combined with everolimus or pembrolizumab in advanced cancers.
Modulation of tumor microenvironment through PDGFRα and KIT inhibition affecting stromal and immune cells.
Demonstrated anti-proliferative effects in endothelial and tumor cells across various malignancies.
Supports delay in tumor progression and reduction in metastatic potential in clinical oncology settings.
Targets pathways involved in tumor angiogenesis more comprehensively than traditional VEGF inhibitors.
Exhibits oral bioavailability suitable for long-term, once-daily administration in cancer therapy.

Therapeutic Or Clinical Uses

Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
First-line therapy for unresectable hepatocellular carcinoma, with weight-based dosing.
Combined therapy with everolimus for advanced renal cell carcinoma following prior anti-angiogenic treatment.
Used with pembrolizumab for advanced endometrial carcinoma not exhibiting microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status.
Management of various solid tumors through targeted multikinase inhibition to control disease progression.
Treatment option when conventional therapies including surgery, radiation, or radioactive iodine are ineffective or unsuitable.
Used in cancers characterized by reliance on VEGFR and FGFR pathways for tumor growth and angiogenesis.
Provides an oral targeted therapeutic option for cancer patients requiring systemic treatment.
Addresses tumors with resistance to prior therapies by targeting multiple signaling pathways simultaneously.
Can be integrated into combination regimens with other antineoplastic agents to enhance clinical outcomes.

Side Or Adverse Effects

Hypertension due to VEGFR inhibition affecting vascular homeostasis.
Gastrointestinal symptoms including nausea, vomiting, diarrhea, and abdominal pain.
Proteinuria reflecting renal endothelial impact and potential nephrotoxicity.
Fatigue and asthenia consistent with systemic cancer therapy effects.
Bleeding events such as epistaxis, heavy menstrual bleeding, or more serious hemorrhages.
Hand-foot syndrome characterized by redness, peeling, itching, or pain of the palms and soles.
Hypothyroidism and abnormal thyroid function tests due to interference with thyroid hormone regulation.
Mouth sores and mucositis impairing oral intake and quality of life.
Respiratory symptoms including cough, hoarseness, and dyspnea.
Jaw osteonecrosis presenting as pain, swelling, numbness, or delayed healing after dental procedures.
Cardiovascular events including chest pain, arrhythmias, and heart failure exacerbation.
Increased risk of gastrointestinal perforation and fistula formation necessitating prompt intervention.
Hepatotoxicity presenting as jaundice, elevated liver enzymes, and cholestatic hepatitis.
Neurological symptoms such as headache, confusion, seizure, or vision changes.
Electrolyte disturbances including hypocalcemia resulting in muscle cramps or tingling sensations.

Precautions

Monitor blood pressure regularly and manage hypertension aggressively during treatment.
Evaluate renal and hepatic function prior to initiation and periodically during therapy.
Assess patient’s cardiac history and monitor for signs of heart failure or arrhythmia.
Carefully assess risk factors for bleeding and gastrointestinal perforation before and during therapy.
Ensure effective contraception for both male and female patients due to teratogenic potential.
Advise against breastfeeding during treatment and for at least one week after discontinuation.
Maintain meticulous dental hygiene, and perform dental evaluations prior to initiation to mitigate osteonecrosis risk.
Modify treatment or interrupt therapy in case of severe adverse effects such as proteinuria or severe diarrhea.
Monitor thyroid function periodically due to potential for thyroid hormone disruption.
Be cautious in patients with a history of seizures or neurological conditions due to risk of CNS side effects.
Avoid concomitant use with strong CYP3A4 inducers or inhibitors without appropriate dose adjustment and monitoring.
Consider temporary discontinuation before surgical or invasive dental procedures to reduce bleeding and wound healing complications.
Counsel patients regarding signs of serious adverse events requiring immediate medical attention.
Use caution in patients with history of QT prolongation or concomitant medications that prolong QT interval.
Ensure careful hydration and nutritional support to reduce risk of dehydration from diarrhea or vomiting.

Warnings

Risk of gastrointestinal perforation or fistula formation; seek emergency care for severe abdominal pain or dysphagia.
Potential for severe bleeding events including bleeding from tumor, nosebleeds, or heavy menstrual bleeding.
Serious cardiovascular toxicities, including hypertension, heart failure, and ischemic events.
Possible development of osteonecrosis of the jaw, particularly in patients with dental disease or prior radiation.
Risk of hepatotoxicity manifesting as jaundice, clay-colored stools, dark urine, or elevated liver enzymes.
May cause severe hypertension leading to hypertensive crisis if not properly managed.
Potential for severe diarrhea causing dehydration and renal impairment; early intervention recommended.
Increased incidence of proteinuria requiring close renal monitoring.
Fetal toxicity: may cause harm or death to unborn baby; not to be used during pregnancy.
Not recommended for breastfeeding due to potential harm to nursing infants.
Neurological adverse effects including seizures, confusion, or vision changes requiring urgent evaluation.
Risk of cardiac arrhythmias and sudden cardiac death in susceptible individuals.
May exacerbate hypothyroidism necessitating thyroid hormone replacement adjustments.
Use with caution in patients with pre-existing wound healing disturbances or recent surgery.
Avoid abrupt discontinuation without medical advice; dosing interruptions should be done under supervision.

Contraindication

Known hypersensitivity to lenvatinib or any of the capsule components.
Pregnancy due to teratogenic and embryotoxic potential of lenvatinib.
Breastfeeding mothers as the drug may harm the nursing infant.
Patients with uncontrolled hypertension or severe cardiovascular disease not adequately stabilized.
Patients with active gastrointestinal perforation or fistula.
Concurrent use of strong CYP3A4 inducers or inhibitors without careful dose adjustment.
History of significant bleeding disorders or active hemorrhagic conditions.
Individuals with severe hepatic impairment where risk outweighs benefits.
Patients unable to swallow or adequately receive oral medication without alternative administration methods.
Known long QT syndrome or patients on medications that prolong QT interval without appropriate monitoring.
Contraindicated in patients with unresolved severe infections or immune-compromising conditions untreated.
Patients with hypersensitivity or severe reactions to other VEGFR or multikinase inhibitors.
Contraindicated in patients with recent major surgery where wound healing could be compromised.
Individuals with a history of osteonecrosis of the jaw unless carefully evaluated and managed.

Drug Interactions

Lenvatinib exposure may be increased by strong CYP3A4 inhibitors, increasing risk of toxicity.
Co-administration with CYP3A4 inducers may reduce lenvatinib plasma concentrations, decreasing efficacy.
Potential additive hypertensive effects when used with antihypertensive drugs require careful monitoring.
Concomitant use with anticoagulants may increase the risk of bleeding complications.
Interactions with other multikinase inhibitors or VEGF pathway inhibitors may exacerbate adverse effects.
Use alongside immunosuppressive agents or chemotherapy may potentiate immune suppression and toxicity.
Drugs that prolong QT interval may have additive cardiac risk when combined with lenvatinib.
Enzyme inducers or inhibitors affecting P-glycoprotein may alter lenvatinib pharmacokinetics.
Osteoporosis medications may have interaction potential requiring dose adjustment or monitoring.
Concurrent use with corticosteroids can increase risk of osteonecrosis of the jaw.
Medications causing hepatotoxicity may compound liver injury risk with lenvatinib.
Antidiabetic drugs require monitoring due to lenvatinib’s potential impact on glucose metabolism.
Interactions with thyroid hormone replacement therapy may necessitate dose adjustments.
Herbal supplements affecting CYP enzymes or coagulation pathways may increase adverse event risk.
Vaccinations and immunomodulating drugs require caution during lenvatinib therapy.

Preparations Of The Drug

Oral capsules available in strengths of 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 18 mg, 20 mg, and 24 mg.
Capsules composed of excipients facilitating dissolution and stable bioavailability.
Packaging designed for protection from moisture and heat; storage at room temperature.
Instructions for patients unable to swallow capsules include dissolving contents in water or apple juice for immediate ingestion.
Formulations intended for once-daily dosing to maximize compliance and therapeutic coverage.
Available as prescription-only medication requiring oncology specialist supervision.
Must be stored away from children and pets to prevent accidental ingestion.
Mixed dissolved preparations to be used within 24 hours and refrigerated during that period.
Manufactured under strict quality control for purity, potency, and safety standards.
Not formulated for intravenous or other routes; oral capsule is the only approved dosage form.
Repackaging or compounding of capsules is not recommended due to stability concerns.
Medication guides and detailed patient instructions provided with each dispensing to ensure proper use.
Preferred to be prescribed in fixed combinations with agents like everolimus or pembrolizumab when indicated.
Monitoring of storage conditions advised to maintain drug integrity over shelf life.
Available internationally under different brand names but identical active pharmaceutical ingredient.